论文部分内容阅读
作为已获食品药物管理局(FDA)批准的美国唯一人生长激素(hGH)生产厂家,Genentech(旧金山,加利福尼亚州)截止到1986年第二季度,其重组hGH销售量已升至950万美元。然而,面对Bio-Technology General(BTG)(纽约,纽约州)以及Ares-Serono(波士顿,马萨诸塞州)的竞争,以上情况可能会有变化。这两家公司都在进行重组的自然hGH的临床检验。Genentech的人生长激素(实际上是甲基人生长激素)由于在肽链终端多一个蛋氨酸残基,在某些病人体中会引起免疫反应。 BTG与Serono均宣称他们的hGH没有这种额外基因引起的反应,尽管BTG公司对98个儿童做的试验才有4个月,但在同样短的期间里用Genentech公司的产品作试验已出现问题。
As the only manufacturer of human growth hormone (hGH) in the United States approved by the Food and Drug Administration (FDA), Genentech (San Francisco, California), as of the second quarter of 1986, its sales of recombinant hGH have risen to $9.5 million. However, the above situation may change in the face of competition from Bio-Technology General (BTG) (New York, NY) and Ares-Serono (Boston, MA). Both companies are conducting clinical tests of recombinant natural hGH. Genentech’s human growth hormone (actually methyl-human growth hormone) causes an immune response in some patients due to an extra methionine residue at the end of the peptide chain. Both BTG and Serono claim that their hGH does not have this extra gene-induced reaction. Although BTG had only 4 months of testing for 98 children, it has been problematic to test using Genentech’s products in the same short period. .